featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

French ophthalmology company GenSight withdraws from US IPO listing on NASDAQ

French gene therapy company GenSight Biologics SA, based in Paris, France, has announced the withdrawal of a planned IPO (initial public offering) on the US NASDAQ, citing market conditions. The company had filed in July 2015 to raise up to $100 million, following a private investment round of €36 million. The company currently has two […]

Read full story
Featured

Sleep apnea and anti-VEGF treatment in AMD patients – a potential under-diagnosis of apnea may account for anti-VEGF non-responders

Collaborative clinical research conducted by teams from the University of Louisville, Kentucky and the Rambam Medical Centre, Haifa Israel, have proposed that treatment of exudative AMD patients with bevacizumab with a co-morbidity of untreated sleep apnoea may result in considerably less effective treatment. In comparison, AMD patients with sleep apnea, and who undergo continuous positive […]

Read full story
Research

AMD continues to be the leading cause of vision loss in England and Wales

Researchers based at the Department of R&D, NIHR BRC for Ophthalmology, Moorfields and UCL Institute of Ophthalmology, London, have reported that the leading cause of certified vision impairment in England and Wales continues to be age-related macular degeneration (AMD). Analysis and review of certificates of vision impairment records showed that for the period from April […]

Read full story
Introduction

April 18th, 2016: “EURETINA-Brief”© Issue No. 131

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the April 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Featured

CRISPR gene editing technology continues to create significant commercial interest including applications to ophthalmology

The recently developed CRISPR gene editing technology is currently generating significant interest in the biomedical community, not least of all due to its low cost, its incredible ease of use and its versatility across a broad range of applications (see Bayer-CRISPR Therapeutics joint venture announcement in our recent issue). Referred to as “clustered regularly interspaced […]

Read full story
Introduction

January 18th, 2016: “EURETINA-Brief”© Issue No. 125

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the January 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story

Latest News

Book Review